|
Additional models:  
Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23))  
PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - (10/18/23))  
Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23))  
Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23))  
Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23))  
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23))  
---------------------------------------------------  
- Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)
 
- CROI: EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035 - (04/02/24)
 
- CROI: First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care - (04/02/24)
 
- CROI: HIV Preexposure Prophylaxis With Emtricitabine
and Tenofovir Disoproxil Fumarate Among Cisgender Women
- (04/02/24)
 
- CROI: A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results - (03/28/24)
 
- CROI:
Cabotegravir Population Pharmacokinetic Analysis of
Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP
- (03/27/24)
 
- CROI:
Why Is Cabotegravir Rollout So Slow?
- (03/27/24)
 
- CROI:
HIV Post-exposure Prophylaxis (PEP) Prescription
Trends (underutilized) - United States, 2013-2022
- (03/27/24)
 
- CROI: PEP2PrEP: an effective HIV risk-reduction strategyn
- (03/27/24)
 
- CROI:
Randomized Trial Shows Huge Uptake Success
of HIV Prevention Choices in Kenya, Uganda
- (03/22/24)
 
- CROI:
US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses - Mark Mascolini (03/18/24)
 
- CROI:
Safety Study of Dapivirine Vaginal Ring and Oral
PrEP for the Prevention of HIV During Early Pregnancy - (03/18/24)
 
- CROI:
Strong Oral PrEP Uptake and Persistence in
3000 African Girls and Young Women in INSIGHT Cohort - Mark Mascolini (03/18/24)
 
- CROI: <
HIV Incidence in Users of HIV Preexposure
Prophylaxis in Australia: A Whole-of-Population Analysis - (03/18/24)
 
- CROI: HIV incidence in users of HIV preexposure prophylaxis
in Australia: a whole-of-population analysis - Mark Mascolini (03/18/24)
 
- CROI:
Associations between a polygenic risk score for Alzheimer's disease and brain integrity in HIV - (03/18/24)
 
- CROI: Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022 - (03/18/24)
 
- CROI: Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP - (03/18/24)
 
- CROI:
Doxycycline Post-Exposure Prophylaxis (DoxyPEP):
High uptake and Significant Decline in STIs after Clinical Implementation - (03/18/24)
 
- CROI:
Randomized Trial Shows Huge Uptake Success
of HIV Prevention Choices in Kenya, Uganda - Mark Mascolini (03/18/24)
 
- CROI:
Phone calls for PrEP persistence in Kenyan
women in postabortal care: a cluster randomized trial. - Mark Mascolini
(03/12/24)
 
- CROI:
PrEP Non-Persistence and New HIV Diagnoses:
A Real-World Analysis of >120,000 People Prescribed PrEP -
(03/12/24)
 
- CROI: Safety of dapivirine vaginal ring and oral PrEP
for HIV prevention in the second trimester. - Mark Mascolini
(03/12/24)
 
- CROI:
CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN
19 U.S. CITIES, 2018 & 2022 ....very low PrEP use -
(03/12/24)
 
- CROI:
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 -
(03/12/24)
 
- CROI: Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP -
(03/12/24)
 
- CROI: Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States -
(03/12/24)
 
- CROI:
Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort -
(03/12/24)
 
- CROI:
Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort -
(03/12/24)
 
- CROI: No Virologic Failures, Good Safety With LA I
njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study - Mark Mascolini (03/11/24)
 
- CROI: High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort - (03/07/24)
 
- CROI:
Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP - (03/07/24)
 
-
HIV Prevention Doubles PrEP Use: auto text messaging+mobile web-app peer support+non-maulaized telehealth coaching by paraprofessionals - (02/27/24)
 
-
HIV pre-exposure prophylaxis provision by U.S. health centers in 2021 - (02/02/24)
 
-
LAI PrEP Barriers & Facilitators US Primary Care Setting - (01/29/24)
 
- Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
- (01/29/24)
 
-
Lenacapavir 5 PrEP Global Studies - (01/29/24)
 
- CROI: ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
 
- CROI: Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection - (02/24/23)
 
-
5 Purpose Studies for Lanacapavir PrEP: Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program - (01/10/24)
 
- Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication - (01/10/24)
 
-
Out-of-pocket cost increase could put
HIV prevention medications out of reach - (01/10/24)
 
- Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (01/10/24)
 
- Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (01/10/24)
 
- TelePrEP in NYC - (01/10/24)
 
- Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness - (01/10/24)
 
- PrEP Use and HIV Incidence Among Youth At-Risk for HIV Infection in Los Angeles and New Orleans: Findings From ATN 149 - (01/10/24)
 
- Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (01/10/24)
 
- Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022 - (01/10/24)
 
- HHS EHE (PrEP) Leaders Reflect on 2023 and Look Ahead to 2024 - (01/09/24)
 
- Understanding Psychosocial Determinants (Beliefs, Attitudes) of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention - (01/09/24)
 
- Advancing the community plan to end the HIV Epidemic in Philadelphia: a qualitative descriptive evaluation of low-threshold PrEP services in sexual health clinics - (01/09/24)
 
- 2 Studies on PrEP for Women IDUs, Demonstrate
PrEP is a Necessary Tool for Women, to EtE
- (01/09/24)
 
- Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019
- (01/08/24)
 
- Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis
- (01/08/24)
 
- Person-centered HIV PrEP for cisgender women
- (01/08/24)
 
- Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
- (01/08/24)
 
- Cocaine Eats Up Brain Twice as Fast as Normal Aging
- (01/08/24)
 
-
Efficacy estimates of oral pre-exposure prophylaxis
for HIV prevention in cisgender women with partial adherence
- (01/08/24)
 
-
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts
- (01/08/24)
 
- ID Week: Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona - (10/24/22)
 
- ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
 
- ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
 
ID Week : Increase in New HIV Diagnoses Following Decrease in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic - (10/16/23)  
Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23)  
Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States - (10/18/23)  
Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23)  
IIntegrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23)  
ID Week : Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors - (10/16/23)  
ID Week : Risk Factors, Risk Perception, and Long-Acting PrEP Awareness and Interest Among US Women: A National Survey - (10/16/23)  
ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)  
ID Week : Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers - (10/13/23)  
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23)  
The First Ten Years of HIV Preexposure Prophylaxis Use and Missed Opportunities at an Urban Academic Children's Hospital - (10/18/23)  
PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - (10/18/23)  
Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network - (10/18/23)  
Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23)  
Investing in National HIV PrEP Preparedness (Over-the-Counter free PrEP) - (09/28/23)  
Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis - (08/11/23)  
IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)  
Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California  
ID Week: Predicted uptake of novel HIV treatment options in the United States - (10/16/23)  
ID Week : Factors driving decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a real-world study in the United States - (10/16/23)  
ID Week : The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US - (10/16/23)  
ID Week : Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System - (10/16/23)  
ID Week : Facilitators and Barriers to Engaging in PrEP and Gender Affirming Therapy for Black and Latina Transgender Women in South Florida - (10/16/23)  
|